According to the 2016 revised WHO classification for lymphoid neoplasms, the co-expression of C-MYC and BCL-2 without associated rearrangements defines an adverse prognostic marker named double-expressor (DE) lymphoma [8,71]. This evidence concerns the gene BCL2 and lymphoid neoplasm.